SQZ® Cell Therapies Seek to Put Your
Immune System to Work Against Disease

About Our Approach

We use a patient’s own cells to manufacture a personalized therapy. After blood collection, we isolate target cell types, use our SQZ® technology to engineer their functions and administer them back to the patient. This manufacturing process typically takes less than 24hrs and a patient can receive their first dose about a week after blood collection. Once administered, SQZ® engineered cells are designed to home to specialized immune structures, such as the lymph nodes and spleen, and direct the patient’s immune system to target disease.

We have clinical programs in oncology and preclinical programs for autoimmune diseases (e.g. celiac disease, type 1 diabetes) and infectious diseases (e.g. chronic hepatitis B).

The Patient Experience

No preconditioning

No lengthy hospital stays

Time to treatment: ~1wk

Administration is a simple syringe push

Patients and their physicians can expect rapid answers to questions about our clinical trials. Your time is important, and we will endeavor to respond with urgency.

Current Active Enrollment · Oncology

SQZ Biotech is actively enrolling in the following trials for patients with HPV+ cancers. Currently, the majority of our clinical trial sites are based in the United States, but we have started to expand to other countries. For patients who do not live near one of our trial sites, we will assist with domestic and international travel and accommodations to the nearest clinical trial hospital and cover all reasonable and related expenses.

Enrolling HPV+ Cancers

  • Anal
  • Cervical
  • Head and Neck
  • Penile
  • Rectal
  • Vaginal
  • Vulvar


  • Male or Female 18 years of age or older
  • Histologically confirmed incurable or metastatic solid tumors that are HPV16+
  • Cancer progression after at least one available standard therapy for incurable disease, or patient is intolerant to or refuses standard therapy(ies) or has a tumor for which no standard therapy(ies) exist
  • HLA-A*02 genotype positive (only for SQZ-PBMC-HPV-101 and ENVOY-001 trials)
APC therapeutic candidate derived from patient’s own white blood cells
  • Designed to present specific tumor antigens to the body’s endogenous CD8 T cells
  • Administered as monotherapy or in combination with checkpoint inhibitors such as atezolizumab, nivolumab, and/or ipilimumab
  • Encouraging initial monotherapy clinical trial data was presented at the 2021 American Society of Clinical Oncology (ASCO) annual meeting. Additional clinical data was presented at ESMO IO 2021 demonstrating a clinical and immune response in a heavily treated patient. See our ESMO-IO press release and oral presentation

Learn about the science behind SQZ-PBMC-HPV-101
Trial and enrollment details
Download Trial Information for Patients

Enhanced APC (eAPC) therapeutic candidate derived from patient’s own white blood cells
  • Designed to leverage the advantages and functionalities of five different mRNAs squeezed into white blood cells
  • Administered as monotherapy or in combination with checkpoint inhibitor pembrolizumab
  • In preclinical studies, SQZ® eAPCs have been shown to generate robust CD8 T cell responses against multiple antigens, through simultaneous expression of antigens, CD86, membrane bound IL-2, and membrane bound IL-12

Learn about the science behind COMMANDER-001
Download Trial Information for Patients

AAC therapeutic candidate derived from patient’s own red blood cells
  • Designed to transport tumor-specific antigen and activating adjuvant to a patient’s own antigen presenting cells in vivo
  • Administered as a monotherapy or in combination with checkpoint inhibitors ipilimumab or nivolumab
  • In preclinical studies, SQZ AACs have demonstrated robust immune responses, CD8 T cell infiltration, and correlated tumor reduction

Learn about the science behind ENVOY-001
Trial and enrollment details
Download Trial Information for Patients

Expanded Access Policy

In expanded access programs, patients with serious diseases or life-threatening conditions who have exhausted all available options and do not meet the eligibility criteria to participate in a clinical trial may be able to access investigational therapies.At this time in our clinical development path, however, we do not offer expanded access as we believe that enrollment in our clinical trials is the best way for us to develop safe and effective treatments that would ultimately benefit a larger number of patients.

We encourage all patients and physicians who are interested in accessing our investigational therapies to contact us for information. You can also visit trial and enrollment details for each trial listed above and see additional details on


  • University of Colorado, Aurora, CO
  • University of Kansas Cancer Center, Kansas City, KS
  • Massachusetts General Hospital, Boston, MA
  • University of Nebraska Medical Center, Omaha, NE
  • Vanderbilt University Medical Center, Nashville, TN
  • The Masonic Cancer Center, University of Minnesota, Minneapolis, MN
  • OU Health Stephenson Cancer Center, Oklahoma City, Oklahoma, OK
  • Princess Margaret Cancer Centre, Toronto, Ontario, Canada
  • University Hospital Cologne, Clinic I for Internal Medicine, Germany


  • HonorHealth, Scottsdale, AZ
  • University of Colorado, Aurora, CO
  • Tenessee Oncology, Nashville, TN
  • More sites expected to open soon!


  • UC San Diego Moores Cancer Center, La Jolla, CA
  • City of Hope, Duarte, CA
  • Barbara Ann Karmanos Cancer Institute, Detroit, MI
  • Roswell Park Comprehensive Cancer Center, Buffalo, NY
  • Oregon Health & Science University, Portland, OR
  • More sites expected to open soon!

Patient Advocacy

We are committed to advancing the clinical development of cell therapies that are safe, effective and accessible to patients worldwide. We are actively engaged with leading advocacy organizations working to support patients and their families living with cancer. For additional information on HPV+ cancers, the following organizations can provide educational and other resources.

We are not responsible for content provided by these organizations.